We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
- Authors
Kir, Gozde; Soylemez, Tuce; Olgun, Zeynep Cagla; Aydin, Abdullah; McCluggage, W. Glenn
- Abstract
Endometrial carcinoma programmed death-ligand 1 (PD-L1) expression in tumor cells (TCs) and tumor-associated inflammatory cells (ICs) have recently been reported in several studies which vary in terms of their cohort size, design, and methodology. We aimed to assess PD-L1 staining in endometrial carcinomas and correlate this with clinical and pathological factors and PTEN, ARID1A, p53, and MMR protein expression. PD-L1 immunohistochemistry was performed on whole tissue sections of all tumor blocks of 59 consecutive unselected endometrial carcinomas between November 2018 and September 2019. TC and IC PD-L1 positivity with a 1% cut-off value was observed in 10.2% and 67.8% of cases, respectively, and with a 5% cut-off value in 3.4% and 42.4% of cases, respectively. TC PD-L1 positivity with both 1% and 5% cut-off values was significantly related to ARID1A loss (p = 0.001 and p = 0.046, respectively). IC PD-L1 positivity with 1% and 5% cut-off values and combined score were significantly associated with MMR protein deficiency (p = 0.041, p = 0.031, and p = 0.028, respectively). Advanced stage tumors exhibited more frequent PD-L1 expression in ICs (p = 0.039). MELF-type myometrial invasion pattern was more common in tumors with ARID1A loss (p = 0.047). We observed higher rates of IC PD-L1 positivity in endometrial carcinomas than documented in prior studies; this may be related to our usage of "recent" paraffin blocks and whole tissue sections of all tumor blocks. There was a much higher PD-L1 expression in the ICs compared to TCs in our cases. We confirm a previously documented association between MMR deficiency and PD-L1 expression and show a novel association between ARID1A loss and PD-L1 expression in endometrial carcinomas. ARID1A loss represents a potential biomarker of immune checkpoint inhibitor response in endometrial carcinoma.
- Subjects
PROGRAMMED death-ligand 1; PROGRAMMED cell death 1 receptors; IMMUNE checkpoint inhibitors; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; BIOMARKERS; PROTEIN deficiency
- Publication
Virchows Archiv: European Journal of Pathology, 2020, Vol 477, Issue 6, p845
- ISSN
0945-6317
- Publication type
Article
- DOI
10.1007/s00428-020-02867-9